These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32862311)

  • 41. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs.
    Schub D; Assmann G; Sester U; Sester M; Schmidt T
    Arthritis Res Ther; 2018 Nov; 20(1):252. PubMed ID: 30413189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
    Barton P; Jobanputra P; Wilson J; Bryan S; Burls A
    Health Technol Assess; 2004 Mar; 8(11):iii, 1-91. PubMed ID: 14982655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton.
    Dubrovsky AM; Lim MJ; Lane NE
    Calcif Tissue Int; 2018 May; 102(5):607-618. PubMed ID: 29470611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Lymphoma in rheumatic diseases].
    Rubbert-Roth A; Bittenbring JT; Assmann G
    Z Rheumatol; 2017 Oct; 76(Suppl 2):46-56. PubMed ID: 29330755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
    Singh JA
    Curr Rheumatol Rep; 2016 Oct; 18(10):61. PubMed ID: 27613285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
    Zhang J; Xie F; Yun H; Chen L; Muntner P; Levitan EB; Safford MM; Kent ST; Osterman MT; Lewis JD; Saag K; Singh JA; Curtis JR
    Ann Rheum Dis; 2016 Oct; 75(10):1813-8. PubMed ID: 26792814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of etanercept in a patient with rheumatoid arthritis on hemodialysis.
    Sugioka Y; Inui K; Koike T
    Mod Rheumatol; 2008; 18(3):293-5. PubMed ID: 18299957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management.
    De Cock D; Hyrich K
    Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):869-886. PubMed ID: 31427060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
    Murdaca G; Spanò F; Puppo F
    Expert Opin Drug Saf; 2013 Nov; 12(6):801-4. PubMed ID: 23889669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic.
    Sahebari M; Mirfeizi Z; Hashemzadeh K; Salavati Nik E; Gholampoor Shamkani N
    Arch Bone Jt Surg; 2022 Nov; 10(11):964-968. PubMed ID: 36561225
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ; Ranganathan P
    Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.